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Edited by Horst FeldmannAbstract MRI has the ability to generate high-contrast and
high-resolution images, to obtain multiple diagnostic evaluations
of organ function and morphology, and to provide multiple image
planes with no risk of ionizing radiation. Recent eﬀorts have fo-
cused on using MR technology to monitor gene delivery, to en-
hance gene transfection/transduction, and to track gene
expression. This review summarizes the current status of MRI-
guided gene therapy.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Gene therapy1. Introduction
Gene therapy is an exciting frontier in medicine today. It is
designed to target the causes rather than the symptoms of dis-
ease. Our current knowledge about the biodistribution and
pharmacokinetics of gene therapy relies mainly on the results
of in vitro laboratory examinations of tissues obtained at
biopsy or autopsy. Thus, it is essential to develop non-invasive
methods to monitor and guide gene therapy.
To date, diﬀerent imaging modalities, such as magnetic res-
onance imaging (MRI), ultrasound, nuclear medicine, and
optical imaging, have been applied to the monitoring of gene
therapy [1]. MRI has several prominent advantages compared
to other imaging techniques, including the ability to generate
high-contrast and high-resolution images, to obtain multiple
diagnostic evaluations of organ function and morphology,
and to provide multiple image planes with no risk of ionizing
radiation. Recent eﬀorts have focused on using MR technol-
ogy to monitor gene delivery, to enhance gene transfection/
transduction, and to track gene expression [2]. This review
summarizes the current status of MRI-guided gene therapy.2. MRI-monitored gene delivery
The eﬃcient delivery of genes to the target is the ﬁrst key
step in successful gene therapy. During the primary gene deliv-
ery procedure, one needs to see how the delivered genes distrib-*Corresponding author. Fax: +90 312 442 6482.
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at a high concentration at the target. An initial study at-
tempted to validate the feasibility of using MRI to monitor
gene delivery to the vessel walls [3]. The authors mixed a mar-
ker gene, green ﬂuorescent protein (GFP) gene carried by a
lentiviral vector, with a T1 MR contrast agent, gadolinium
(Gd). The GFP–Gd mixture was then locally transferred into
swine artery walls via a catheter-based approach, while the
delivery process was monitored under real-time MRI. Cross-
sectional magnetic resonance images showed an enhanced
bright ring as the GFP–Gd mixture was transferred into the ar-
tery wall, which correlated with GFP-positive cells of the arte-
rial tissues according to subsequent histological staining.
Another attempt was to evaluate the possibility of using
MRI to monitor agent delivery to the prostate under MRI
guidance [4,5]. After percutaneously positioning an MR-com-
patible biopsy needle into the prostate, the authors used MRI
to visualize the distribution of a Gd–trypan blue mixture that
was injected into the prostate via a biopsy needle. The results
of this study show an accurate correlation between MRI and
histology with regard to the intra-prostate distribution of
Gd–blue mixture (Fig. 1).
Intraluminal MRI may greatly facilitate the development of
MRI-guided gene therapy in other organs and systems. For
example, recent studies have demonstrated the feasibility of
generating intraluminal MRI of non-cardiovascular systems,
such as the esophagus [6] and hepatobiliary system [7]. These
intraluminal MRI techniques enable us to (a) observe the lumi-
nal walls at high-resolution scales; and (b) combine the intra-
luminally placed MR devices with diﬀerent existing
interventional procedures, including gene therapy. These
advantages of intraluminal MRI should provide further
opportunities to use MRI to guide and monitor gene therapies
in various organs and systems of the body.3. MRI-enhanced gene expression
One of the current limitations of gene therapy is its low
capability to suﬃciently transfect/transduce genes/vectors into
the targets. For example, the in vivo transfection/transduction
of genes in vasculatures is very low, e.g., approximately only
1% for non-viral gene-carrying vectors and less than 5% for
viral gene-carrying vectors [8,9]. To overcome this problem,
imaging scientists have begun to explore the potential of com-
bining MR techniques with other techniques, such as radiofre-
quency (RF) and focused-ultrasound, to enhance gene transfer
and gene expression.ation of European Biochemical Societies.
Fig. 1. Human injection trials: Histology and magnetic resonance monitoring of distributions show close agreement. First column: A 0.018-in.
diameter nitinol injection needle was placed by hand into the prostate, and T1-weighted gradient echo images were acquired. Second column:
Following injection of 0.3 ml of 30 mM Gd–DTPA, mixed with trypanblue tissue dye (over 30 s), a second set of T1-weighted gradient echo images
was acquired. Enhancement due to the gadolinium solution is clearly visible. Third column: Blue stained tissue, seen in gross tissue sections of the
prostate, corresponds well with the enhancement seen in MR images [5].
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tion and expression is based on the fact that RF can create lo-
cal heat. A few in vitro studies have demonstrated that
controlled heating can enhance gene transfection, with the pro-
posed mechanisms of (a) fracturing tissues by heat; (b) increas-
ing the permeability of the plasma membrane and cell
metabolism; and (c) increasing of the activity of heat-sensitive
heat shock proteins [10–12]. Recent eﬀorts have focused on the
combination of MRI and RF-enhanced vascular gene expres-
sion. Using a loopless MR antenna as an intravascular heat
delivery vehicle, investigators ﬁrst designed an intravascular
MR/RF system [13,14], which enabled generation of not only
local RF heat but also MR thermal mapping to monitor and
control the RF heat distribution at the targeted vessels [13].
In the subsequent in vitro and in vivo studies, the authors have
further evaluated the feasibility of using the intravascular MR/
RF system to enhance vascular gene expression [15], and to en-
hance vascular endothelial growth factor (VEGF) gene ther-
apy of in-stent neointimal hyperplasia (Fig. 2) [16].
The principle of low-frequency ultrasound (US)-enhanced
gene transfection/transducion and expression is based on the
fact that ultrasound may induce cell-membrane porosity, re-
duce the thickness of the unstirred layer at the cell surface,
and facilitate the passage of genes/vectors across cell mem-
branes [17,18]. However, low-frequency ultrasound does not
oﬀer high-resolution imaging of the gene-targeted vessel wall
and may be technically feasible only when treating superﬁcial
organs due to diﬃculties in precisely focusing the ultrasound
power in deep structures. To deal with this problem, investiga-
tors have developed a method that uses MRI to guide the
direction of focused-ultrasound energy to the targets, and thus,
enhance gene expression at the targets.A non-invasive, physical approach to the combination of
MRI-guided focused ultrasound (MRI-FUS) with a heat-sen-
sitive promoter (hsp) was reported to help the enhancement
of gene expression [10,19]. In one study with natural hsp70
induction in rat leg by MRI-FUS, investigators demonstrated
increased expression of the hsp70 mRNA at the MRI-FUS-
treated region [10]. In another study, a stable modiﬁed C6 gli-
oma cell line was used to carry a fused gene coding for thymi-
dine kinase (TK) and green ﬂuorescent protein (GFP) under
control of the human hsp 70 promoter. In vivo tumors were
subjected to a 3-min temperature elevation using MRI-FUS
with a constant temperature, and were analyzed 24 h after
the heat shock for GFP ﬂuorescence. Preliminary results
showed the elevated expression of TK-GFP [10,19]. In addi-
tion, some authors have reported that the blood–brain barrier
can be consistently opened with focused ultrasound exposures
in the presence of an ultrasound contrast agent. Indeed, MR
imaging signal intensity changes may be useful in the detection
of blood–brain barrier opening during sonication [20]. The
interesting point here is that therapeutic genes may be carried
by liposome- or polymer-based ultrasound contrast, which
may then permit high doses of genes to pass through the
blood–brain barrier and enhance gene therapy in the neurolog-
ical system under MRI guidance.4. MRI tracking of gene expression
After therapeutic genes are successfully transferred into the
targets, gene expression must be tracked, basically to discover
(a) at what level genes express, and (b) for how long genes
function at the targets. Currently, it is not possible to directly
Fig. 2. Microscopy examination of stented arteries with VEGF gene therapy only (A) and with intravascular MR/RF-enhanced VEGF gene therapy
(B). In-stent neointimal hyperplasia (open arrow) is thinner in VEGF/RF-treated artery (B) than in VEGF-only-treated artery (A). H&E staining,
68X.
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ing modality. As molecular imaging rapidly emerges as a bio-
medical research discipline, imaging scientists have promoted
the concept of using MRI as a non-invasive imaging tool to
monitor, in vivo, speciﬁc molecular and cellular processes,
for example, gene expression. MRI tracking of gene expression
is primarily based on the ability of MRI to detect gene-ex-
pressed downstream products, such as proteins and enzymes.
The initial investigations of MRI tracking of gene expression
were focused on imaging of introduced genes, which express
MR substrate-attractable receptors or enzymes, into the tar-
gets. The receptors or enzymes can bind or metabolize para-
magnetic substrates to the target at high concentrations,
which then generate MR signals at the targets [21]. For exam-
ple, the human transferrin receptor (TfR) genes express, on the
cell surface, high-level TfRs on a variety of tumor cell types,
which then can be imaged using transferrin (Tf)-bound super-
magnetic contrast agents [22]. Tyrosinase, an enzyme normally
involved in melanogenesis at the target, can remarkably bind
metals, such as iron, which thus produces high signal intensity
on T1-weighted images [23]. The principle of tyrosinase-in-
duced MRI is primarily based on the mechanism of tyrosinase
in catalyzing the conversion of low-relaxivity substrates into
high-relaxivity products.
Recent progress in nanotechnology has opened up new
avenues for extending the usefulness of MRI to track gene
expression. Micro/nanoparticle-based MR imaging of geneFig. 3. Dual gene-carrying plasmid is constructed within a lentiviral vector, w
and a therapeutic protein, the VEGF, at the target cell. Transferrin-conjugate
which is then imaged by MRI. Thus, the success of directly detecting the Tfexpression depends primarily on the production of smart con-
trast agents to target speciﬁc biochemical pathways, such as a
receptors or enzymes that are expressed or activated by the
transferred genes at the targets. A functional smart contrast
agent requires the conjugation of a ligand with MR-detectable
nanoparticles or MR contrast agent molecules. Thus, once
transgenes express the downstream receptors, such as cell-sur-
face receptors, the systemically delivered MR smart contrast
agents can concentrate speciﬁcally on these expressed receptors
via the receptor–ligand interaction (pair), which has been re-
ferred to as ‘‘cell-surface receptor imaging’’ [24]. A recent
study also reported the synthesis of two novel gadolinium-
bisamides, which were designed as enzyme-activated contrast
agents for MRI, with a net increase in longitudinal (R1) relax-
ivity [25].
The gene-expressed receptors or enzymes mentioned above
are actually considered MRI reporters or markers for the gen-
eration of MR imaging. Our ﬁnal goal in developing the tech-
nology of MRI for gene therapy is to detect the expression of a
given therapeutic gene rather than that of a marker gene. To
this end, it is essential to build dual gene-carrying vectors,
which carry and express simultaneously two genes, a reporter
gene (such as TfR gene), and a therapeutic gene (such as
VEGF gene). Thus, the indirect assessment of functional
VEGF gene expression can be achieved by the direct detection
of TfR gene expression since two genes are simultaneously ex-
pressed from the same vector (Fig. 3).hich thus expresses simultaneously an MR imaging reporter, the (TfR),
d smart MR contrast agents bind TfRs via the receptor–ligand binding,
R by MRI indicates indirectly the functionality of the VEGF.
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One of the prominent advantages of MRI is its ability to
generate not only anatomic imaging for observation of organ
morphology, but also functional imaging for assessment of or-
gan perfusion, and metabolic and mechanical functions. This
unique advantage makes MRI a powerful tool for the fol-
low-up of a given gene therapy. For example, after gene ther-
apy of cardiac ischemia/infarction, one may use perfusion
MRI to evaluate the recovery of ischemic tissues, MR tagging
to assess the mechanical properties of the gene-treated cardiac
region, and spectroscopic imaging to examine the metabolic
status of the gene-treated heart. Targets for vascular gene ther-
apy currently include limiting restenosis after balloon angio-
plasty and stent placement, inhibiting vein bypass graft
intimal hyperplasia/stenosis, therapeutic angiogenesis for car-
diac and lower-limb ischemia, and prevention of thrombus for-
mation [26]. While catheter angiography is still the standard
method by which to follow vascular gene transfer, advanced
MR techniques, such as MR angiography and perfusion MR
imaging, are becoming useful non-invasive methods by which
to assess the success of gene therapy in vascular diseases.6. Conclusion
Gene therapy is a promising approach to the treatment of
many forms of disease, including cancer. MR technology is
an important imaging tool in this era. The development of
intraluminal MR techniques provides a great opportunity to
combine MRI with exciting interventional techniques, which
permits precise monitoring of the biodistribution of the deliv-
ered genes/vectors to the targets under MRI guidance. The
MR thermomapping technique should play a critical role in
the control of the RF- and focused ultrasound-mediated
enhancement of gene expression. Target-speciﬁc molecular
MR imaging associated with nanotechnology has already of-
fered basic medical science an extremely useful in vivo evalua-
tion tool for the non-invasive or minimally invasive imaging of
gene therapy. Functional MR imaging obtained pre- and post-
gene therapy should become an ideal approach to assess the
success of gene therapy. While there are still many challenges
that face MR imaging, the growing number of MRI applica-
tions in the ﬁeld of gene therapy represents a bright future
for MR imaging in modern medicine.References
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